High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancer
Abstract Background Programmed death ligand 1 (PD‐L1) inhibitor has been approved as one of the standard therapies for various cancers. Some reports have shown that serum PD‐L1 level is associated with advanced tumor stages and poor prognosis; however, corresponding pathological information in esoph...
Main Authors: | Masaaki Ito, Satoshi Yajima, Takashi Suzuki, Yoko Oshima, Tatsuki Nanami, Makoto Sumazaki, Fumiaki Shiratori, Kimihiko Funahashi, Naobumi Tochigi, Hideaki Shimada |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-02-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2789 |
Similar Items
-
Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer
by: Ji Ma, et al.
Published: (2023-02-01) -
An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01) -
Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysisResearch in context
by: Zhen Gao, et al.
Published: (2023-09-01) -
PD-1 Inhibitors in the Advanced Esophageal Cancer
by: Ye Hong, et al.
Published: (2019-11-01) -
A case of Barrett’s esophageal cancer with gastric mucosa-associated lymphoma
by: Fumiaki Shiratori, et al.
Published: (2020-08-01)